These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 21690464)

  • 1. Prospective multi-institutional study evaluating the performance of prostate cancer risk calculators.
    Nam RK; Kattan MW; Chin JL; Trachtenberg J; Singal R; Rendon R; Klotz LH; Sugar L; Sherman C; Izawa J; Bell D; Stanimirovic A; Venkateswaran V; Diamandis EP; Yu C; Loblaw DA; Narod SA
    J Clin Oncol; 2011 Aug; 29(22):2959-64. PubMed ID: 21690464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate cancer detection in the "grey area" of prostate-specific antigen below 10 ng/ml: head-to-head comparison of the updated PCPT calculator and Chun's nomogram, two risk estimators incorporating prostate cancer antigen 3.
    Perdonà S; Cavadas V; Di Lorenzo G; Damiano R; Chiappetta G; Del Prete P; Franco R; Azzarito G; Scala S; Arra C; De Sio M; Autorino R
    Eur Urol; 2011 Jan; 59(1):81-7. PubMed ID: 20947244
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial.
    Partin AW; Brawer MK; Bartsch G; Horninger W; Taneja SS; Lepor H; Babaian R; Childs SJ; Stamey T; Fritsche HA; Sokoll L; Chan DW; Thiel RP; Cheli CD
    J Urol; 2003 Nov; 170(5):1787-91. PubMed ID: 14532777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Prostate Cancer Prevention Trial and European Randomized Study of Screening for Prostate Cancer risk calculators indicating a positive prostate biopsy: a comparison.
    van den Bergh RC; Roobol MJ; Wolters T; van Leeuwen PJ; Schröder FH
    BJU Int; 2008 Nov; 102(9):1068-73. PubMed ID: 18715246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostatic volume and volume-adjusted prostate-specific antigen as predictive parameters for T1c prostate cancer.
    Tanaka N; Fujimoto K; Yoshikawa M; Tanaka M; Hirao Y; Kondo H; Saito I
    Hinyokika Kiyo; 2007 Jul; 53(7):459-65. PubMed ID: 17702178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Percentage of free prostate-specific antigen: implications in modern extended scheme prostate biopsy.
    Lee BH; Moussa AS; Li J; Fareed K; Jones JS
    Urology; 2011 Apr; 77(4):899-903. PubMed ID: 21146865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk stratification and validation of prostate specific antigen density as independent predictor of progression in men with low risk prostate cancer during active surveillance.
    San Francisco IF; Werner L; Regan MM; Garnick MB; Bubley G; DeWolf WC
    J Urol; 2011 Feb; 185(2):471-6. PubMed ID: 21167525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combining biomarkers to detect disease with application to prostate cancer.
    Etzioni R; Kooperberg C; Pepe M; Smith R; Gann PH
    Biostatistics; 2003 Oct; 4(4):523-38. PubMed ID: 14557109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development, validation, and head-to-head comparison of logistic regression-based nomograms and artificial neural network models predicting prostate cancer on initial extended biopsy.
    Kawakami S; Numao N; Okubo Y; Koga F; Yamamoto S; Saito K; Fujii Y; Yonese J; Masuda H; Kihara K; Fukui I
    Eur Urol; 2008 Sep; 54(3):601-11. PubMed ID: 18207312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection.
    Jansen FH; van Schaik RH; Kurstjens J; Horninger W; Klocker H; Bektic J; Wildhagen MF; Roobol MJ; Bangma CH; Bartsch G
    Eur Urol; 2010 Jun; 57(6):921-7. PubMed ID: 20189711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive modeling for the presence of prostate carcinoma using clinical, laboratory, and ultrasound parameters in patients with prostate specific antigen levels < or = 10 ng/mL.
    Garzotto M; Hudson RG; Peters L; Hsieh YC; Barrera E; Mori M; Beer TM; Klein T
    Cancer; 2003 Oct; 98(7):1417-22. PubMed ID: 14508828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measurement of prostate specific antigen complexed to alpha1-antichymotrypsin to avoid unnecessary biopsy in patients with serum prostate specific antigen levels 4-20 ng/mL.
    Nakano Y; Okamura K; Takamura S; Okamoto N; Narishima M; Yoshino Y; Hattori R; Ono Y; Ohshima S; Nagasaka T
    Int J Urol; 2005 Aug; 12(8):721-7. PubMed ID: 16174045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate cancer gene 3 and multiparametric magnetic resonance can reduce unnecessary biopsies: decision curve analysis to evaluate predictive models.
    Busetto GM; De Berardinis E; Sciarra A; Panebianco V; Giovannone R; Rosato S; D'Errigo P; Di Silverio F; Gentile V; Salciccia S
    Urology; 2013 Dec; 82(6):1355-60. PubMed ID: 24080222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Percent free prostate-specific antigen (PSA) is an accurate predictor of prostate cancer risk in men with serum PSA 2.5 ng/mL and lower.
    Walz J; Haese A; Scattoni V; Steuber T; Chun FK; Briganti A; Montorsi F; Graefen M; Huland H; Karakiewicz PI
    Cancer; 2008 Nov; 113(10):2695-703. PubMed ID: 18853417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Measurement of insulin-like growth factor axis does not enhance specificity of PSA-based prostate cancer screening.
    Oliver SE; Holly J; Peters TJ; Donovan J; Persad R; Gillatt D; Pearce A; Hamdy FC; Neal DE; Gunnell D
    Urology; 2004 Aug; 64(2):317-22. PubMed ID: 15302487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of several combinations of free, complexed, and total PSA in the diagnosis of prostate cancer in patients with urologic symptoms.
    Filella X; Truan D; Alcover J; Quintó L; Molina R; Luque P; Coca F; Ballesta AM
    Urology; 2004 Jun; 63(6):1100-3; discussion 1103-4. PubMed ID: 15183958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correction of prostate-specific antigen velocity for variation may improve prediction of cancer following prostate repeat biopsy.
    Kumar A; Godoy G; Taneja SS
    Can J Urol; 2009 Jun; 16(3):4655-9. PubMed ID: 19497172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Re: Correction of prostate-specific antigen velocity for variation may improve prediction of cancer following prostate repeat biopsy.
    Singh A
    Can J Urol; 2009 Jun; 16(3):4659. PubMed ID: 19497173
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of systematic 12-core biopsy on the performance of percent free prostate specific antigen for prostate cancer detection.
    Canto EI; Singh H; Shariat SF; Kadmon D; Miles BJ; Wheeler TM; Slawin KM
    J Urol; 2004 Sep; 172(3):900-4. PubMed ID: 15310993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Free-to-total prostate-specific antigen ratio as a predictor of non-organ-confined prostate cancer (stage pT3).
    Aus G; Becker C; Lilja H; Khatami A; Pihl CG; Hugosson J
    Scand J Urol Nephrol; 2003; 37(6):466-70. PubMed ID: 14675918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.